A number of firms have modified their ratings and price targets on shares of Eli Lilly and Company (NYSE: LLY) recently:
- 8/15/2026 – Eli Lilly and Company was upgraded by Wall Street Zen from “buy” to “strong-buy”.
- 8/11/2026 – Eli Lilly and Company was downgraded by Weiss Ratings from “buy (b)” to “buy (b-)”.
- 8/7/2026 – Eli Lilly and Company was given a new $1,376.00 price target by UBS Group AG.
- 8/7/2026 – Eli Lilly and Company had its price target raised by Truist Financial Corporation from $1,370.00 to $1,376.00. They now have a “buy” rating on the stock.
- 8/6/2026 – Eli Lilly and Company had its “overweight” rating reaffirmed by Morgan Stanley. They now have a $1,419.00 price target on the stock.
- 8/6/2026 – Eli Lilly and Company had its price target raised by Wells Fargo & Company from $1,280.00 to $1,330.00. They now have an “overweight” rating on the stock.
- 8/6/2026 – Eli Lilly and Company had its “outperform” rating reaffirmed by BMO Capital Markets. They now have a $1,400.00 price target on the stock.
- 8/6/2026 – Eli Lilly and Company had its price target raised by Cantor Fitzgerald from $1,350.00 to $1,410.00. They now have an “overweight” rating on the stock.
- 7/18/2026 – Eli Lilly and Company was downgraded by Wall Street Zen from “strong-buy” to “buy”.
- 7/15/2026 – Eli Lilly and Company had its price target raised by Citigroup Inc. from $1,500.00 to $1,600.00. They now have a “buy” rating on the stock.
- 7/14/2026 – Eli Lilly and Company had its price target raised by Sanford C. Bernstein from $1,300.00 to $1,385.00. They now have an “outperform” rating on the stock.
- 7/14/2026 – Eli Lilly and Company had its price target raised by Sanford C. Bernstein from $1,300.00 to $1,385.00. They now have an “outperform” rating on the stock.
- 7/13/2026 – Eli Lilly and Company had its price target raised by UBS Group AG from $1,250.00 to $1,425.00. They now have a “buy” rating on the stock.
- 7/13/2026 – Eli Lilly and Company had its price target raised by Guggenheim from $1,235.00 to $1,273.00. They now have a “buy” rating on the stock.
- 7/10/2026 – Eli Lilly and Company had its price target raised by Bank of America Corporation from $1,251.00 to $1,334.00. They now have a “buy” rating on the stock.
- 7/9/2026 – Eli Lilly and Company was given a new $1,370.00 price target by UBS Group AG.
- 7/8/2026 – Eli Lilly and Company had its price target raised by Truist Financial Corporation from $1,281.00 to $1,370.00. They now have a “buy” rating on the stock.
- 7/8/2026 – Eli Lilly and Company had its price target raised by Morgan Stanley from $1,344.00 to $1,347.00. They now have an “overweight” rating on the stock.
- 7/8/2026 – Eli Lilly and Company had its price target raised by Royal Bank Of Canada from $1,250.00 to $1,500.00. They now have an “outperform” rating on the stock.
- 7/7/2026 – Eli Lilly and Company had its price target raised by JPMorgan Chase & Co. from $1,300.00 to $1,400.00. They now have an “overweight” rating on the stock.
- 7/6/2026 – Eli Lilly and Company had its price target raised by Cantor Fitzgerald from $1,230.00 to $1,350.00. They now have an “overweight” rating on the stock.
- 7/1/2026 – Eli Lilly and Company was upgraded by Weiss Ratings from “buy (b-)” to “buy (b)”.
- 6/25/2026 – Eli Lilly and Company had its price target raised by Leerink Partners from $1,119.00 to $1,232.00. They now have an “outperform” rating on the stock.
- 6/22/2026 – Eli Lilly and Company had its “overweight” rating reaffirmed by Cantor Fitzgerald.
- 6/22/2026 – Eli Lilly and Company had its price target raised by Berenberg Bank from $1,050.00 to $1,135.00. They now have a “hold” rating on the stock.
Eli Lilly and Company Announces Dividend
The company also recently declared a quarterly dividend, which will be paid on Thursday, September 10th. Shareholders of record on Friday, August 14th will be given a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, August 14th. This represents a $6.92 annualized dividend and a yield of 0.6%. Eli Lilly and Company’s dividend payout ratio is presently 23.22%.
Insiders Place Their Bets
In other news, EVP Anat Hakim sold 5,000 shares of the stock in a transaction dated Friday, August 7th. The shares were sold at an average price of $1,190.00, for a total transaction of $5,950,000.00. Following the completion of the sale, the executive vice president directly owned 11,875 shares in the company, valued at approximately $14,131,250. This represents a 29.63% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Donald A. Zakrowski sold 2,000 shares of the firm’s stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $1,185.01, for a total value of $2,370,020.00. Following the completion of the sale, the chief accounting officer directly owned 1,526 shares in the company, valued at $1,808,325.26. The trade was a 56.72% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.14% of the stock is owned by company insiders.
Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.
See Also
- Five stocks we like better than Eli Lilly and Company
- Commodities Are Booming, But These 3 ETFs Tell Different Stories
- 3 Active ETFs Making Big Moves in August
- This ETF Is Outperforming by Avoiding the S&P 500’s Biggest Problem
- Birkenstock Beats the Skeptics—But Not on EPS
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.
